GHB and ketamine should be added to the panel of drugs we screen at the point of care in the Amsterdam acute setting.
No takes yet. Share an insight, caveat, or question.
Schaar et al. (2020) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: